We are live on ! Find out more
BBH icon

VanEck Biotech ETF

111 hedge funds and large institutions have $125M invested in VanEck Biotech ETF in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

15% more capital invested

Capital invested by funds: $109M → $125M (+$16.5M)

5% more funds holding

Funds holding: 106111 (+5)

3.26% more ownership

Funds ownership: 29.97%33.22% (+3.3%)

14% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 28

67% less call options, than puts

Call options by funds: $757K | Put options by funds: $2.29M

Holders
111
Holders Change
+5
Holders Change %
+4.72%
% of All Funds
1.35%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
24
Reduced
28
Closed
14
Calls
$757K
Puts
$2.29M
Net Calls
-$1.53M
Net Calls Change
-$1.02M
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$19.3M -$1.34M -7,219 -7%
Raymond James Financial
2
Raymond James Financial
Florida
$13.6M +$407K +2,202 +3%
Morgan Stanley
3
Morgan Stanley
New York
$11.2M +$5.06M +27,350 +86%
Bank of America
4
Bank of America
North Carolina
$8.7M +$651K +3,519 +8%
MIM
5
Miller Investment Management
Pennsylvania
$7.37M -$7.74M -41,833 -52%
LPL Financial
6
LPL Financial
California
$6.02M +$2.29M +12,351 +63%
Wells Fargo
7
Wells Fargo
California
$5.56M +$249K +1,344 +5%
UBS Group
8
UBS Group
Switzerland
$3.82M +$254K +1,374 +7%
BFG
9
Bleakley Financial Group
New Jersey
$3.36M +$41.3K +223 +1%
CCA
10
Conservest Capital Advisors
Pennsylvania
$3.12M +$230K +1,243 +8%
PPWM
11
Paragon Private Wealth Management
Kentucky
$2.76M +$222K +1,199 +9%
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$2.51M -$204K -1,103 -8%
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$2.25M +$185 +1 +0%
Two Sigma Investments
14
Two Sigma Investments
New York
$2.23M +$2.18M +11,800 New
Corient Private Wealth
15
Corient Private Wealth
Florida
$2.08M +$1.1M +5,961 +119%
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$1.83M -$89.9K -486 -5%
LJAC
17
L.J. Altfest & Co
New York
$1.63M -$44.2K -239 -3%
IFWM
18
Institute for Wealth Management
Colorado
$1.41M -$3.88K -21 -0.3%
AGC
19
Aspen Grove Capital
Colorado
$1.41M -$470K -2,540 -25%
PGFC
20
Peapack-Gladstone Financial Corp
New Jersey
$1.36M -$925 -5 -0.1%
Stifel Financial
21
Stifel Financial
Missouri
$1.3M +$40.5K +219 +3%
HighTower Advisors
22
HighTower Advisors
Illinois
$1.25M -$2.04K -11 -0.2%
Ameriprise
23
Ameriprise
Minnesota
$1.21M -$14.6K -79 -1%
Cerity Partners
24
Cerity Partners
New York
$1.1M
ACA
25
Atlas Capital Advisors
Wyoming
$1.08M +$1.05M +5,700 New

BBH Hedge Fund Activity: Q4 2025 in Review

111 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2025, worth a combined $125M — up 15% from $109M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new BBH positions and 14 closed out — a net gain of 6 holders — while 24 added to existing stakes and 28 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.06M. The largest seller was Miller Investment Management, cutting an estimated $7.74M.

  • 111 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2025, up from 106 in Q3 2025.
  • Funds reported $125M of VanEck Biotech ETF stock for Q4 2025, up 15% quarter-over-quarter.
  • 20 funds opened new VanEck Biotech ETF positions in Q4 2025 and 14 closed out, a net change of +6 holders.
  • The largest VanEck Biotech ETF buyer in Q4 2025 was Morgan Stanley, an estimated $5.06M added.
  • The largest VanEck Biotech ETF seller in Q4 2025 was Miller Investment Management, an estimated $7.74M sold.

Based on aggregated 13F filings for Q4 2025.